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T Cell Responses Minireview
and Viral Escape
I MHC molecules puts the number of effector CTLs in
acute infection with this and other viruses much higher,
often well in excess of 10% of CD81 T cells (reviewed
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in McMichael and O'Callaghan, 1998). Analysis of T cellOxford OX3 9DS
receptors on CD81 T cells in the blood of acutely in-United Kingdom
fected patients often shows expansions of oligoclonal
CD81 T cells in HIV that are consistent with these high
numbers (Pantaleo et al., 1994).The CTL responses peak
Virus infections are normally controlled, and often elimi-
as the viraemia starts to fall, and then the expanded T
nated, by T lymphocyte responses. Antibody may also
cell populations fade because of apoptosis. All of this
contribute but is probably more important in prophylaxis
happens before any neutralizing antibody is detectable
against repeat exposure with the same pathogen. Some (Koup et al., 1994). It is widely believed that this CTL
viruses are not eliminated and it is becoming clear that response plays a large part in early and late containment
many of these have evolved immune evasion mecha-
of HIV infection, but there is an alternative view, that the
nisms; herpes viruses, for instance, encode proteins that
infection is limited only by the availability of infectable
interfere with the presentation of viral peptide antigens cells (Phillips, 1996). The latter hypothesis could explain
to T cells (reviewed in Wiertz et al., 1997). However, the rise in HIV load when patients are temporarily in-
despite these immune avoidance strategies, most per- fected with other pathogens, which cause proliferation
sisting viruses remain under control for the life of the of (HIV-susceptible) Th cells specific for that microor-
host. Human immunodeficiency virus (HIV) provokes a ganism, and also the rapid increase in HIV to pretreat-
strong T cell immune response, but unlike most other ment levels when it escapes from antiretroviral drug
virus infections this is insufficient to control the infection control. This hypothesis assumes that the CTL response
permanently. It is becoming clear that the virus can use fails to control the burst in HIV growth in both cases.
an array of immune escape strategies, some of which However, it is now clear that effective anti-HIV drug
are unique to this virus. therapy reduces the cytotoxic T cell response, so that
Helper T Cell Responses to HIV escaping virus confronts a weakened CTL response
A central reason for the failure of the immune response (Ogg et al., 1998).
to adequately control HIV must be that theCD41 T helper Further evidence that CTLs temporarily control HIV
(Th) cells, that respond to the virus, are its targets. Den- infection comes from several sources (reviewed by Row-
dritic cells, which play a central role in antigen presenta- land-Jones et al., 1997). These T cells readily inhibit HIV
tion to Th lymphocytes, can also be infected with HIV replication in cell lines in vitro, both by cytolysis and
and can therefore focus the virus on the most suscepti- release of chemokines and other cytokines (Yang et al.,
ble cells, just as they are stimulated by antigen to prolif- 1997). In vivo, in the persistent phase of infection there
erate (Pope et al., 1994). The Th cell response to HIV has is an inverse correlation between plasma RNA virus load
always been hard to investigate because of difficulties in and the level of circulating effector CTL, measured by
generating any response at all in vitro. Recently Rosen- HLA-epitope tetramer binding (Ogg et al., 1998). This
berg et al. (1997) showed that CD41 T cell responses to relationship is consistent with CTL killing many virus-
an HIV antigen, Gag, could be observed in a few long- infected cells before they produce new virus. Viral pro-
term survivors with very slowly progressing disease. teins and therefore peptide epitopes are generated sev-
They also showed that CD41 T cells responding to Gag eral hours before new virus particles are released (Yang
could be identified in patients treated very early after et al., 1997). The ability of CTL to kill infected cells at
infection; inhibition of virus replication by the drug res- this stage should exert strong selective pressure on the
cued the Th response. This implies that the HIV-specific virus to escape and a number of mechanisms have been
Th response starts normally but, in the absence of drug described (Figure 1). These evasive strategies that are
treatment, is aborted by infection of the responding T directed at the CTL response testify to the importance
cells. The result is, in effect, a state of Th cell tolerance of these T cells in controlling the virus.
to HIV by clonal deletion. This in turn is likely to impair Mutational Escape of HIV-1 from CTL
other types of immune responses to HIV, such as anti- Epitope variation could lead to virus escape from CTL.
body production, because these responses are Th de- HIV replication is error-prone and the huge turnover of
pendent. virus should generate every possible single mutation
Cytotoxic T Cell Responses to HIV many times every day. If CTLs are important, mutations
Despite the compromised Th cell response, infected at critical amino acids in the epitopes recognized should
patients make strong CD81 cytotoxic T lymphocyte be selected. There are very well-documented examples
(CTL) responses to HIV. Measurements of HIV-specific of HIV escape by this mechanism (Table 1).
CTL in the acute phase by limiting dilution analysis show The first example was found following an attempt to
precursor frequencies peaking at over 1% of peripheral treat an HIV-infected patient by adoptive transfer of a
blood CD81 T cells (Koup et al., 1994; Borrow et al., CTL clone, which had been grown to a very largenumber
1997). However, this is an underestimate: direct staining (Koenig et al., 1995). The CTL clone recognized a Nef
of antigen-specific CD81 T cells with tetrameric com- epitope presented by HLA A3. The clinical response was
disappointing with no reduction in virus load or rise inplexes of epitope peptide bound to the presenting class
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Table 1. Mutations Selected by CTL Abrogate Epitope
Presentation by HLA Molecules
Epitope
Patients HLAÐProtein Mutants Reference
CTL transfer HLA A3 QVPLRMTYK Koenig et al., 1995
Nef 69±78 .........
Acute HLA B44 AENLWVTVY Borrow et al., 1997
infection Env 30±38 -G-------
-A-------
-K-------
Acute HLA B8 FLKEKGGL Price et al., 1997
infection Nef 86±93 ----E---
----N---
----Q---
.........
2 patients, HLA B27 KRWIILGLNK Goulder et al., 1997
late Gag 263±272 -K--------
infection
In each case the upper sequence indicates the initial sequence and
those below, the replacement sequences. With the exception of the
A3-Nef epitope, the initial sequence was completely replaced by
the mutants shown. The anchor residues involved in binding to the
HLA molecule are underlined; either these are changed or the whole
epitope is deleted (shown as .........).
Figure 1. CTL Evasion Mechanisms Used by HIV crucial for binding HLA B8, or deleted it. Changes in
The larger upper cell represents an HIV-infected cell with integrated the ratio of nonsynonymous to synonymous nucleotide
provirus generating new virions, virus proteins, and peptides that mutations in the region of the epitope during this period
are presented by HLA class I molecules. Antigen-specific CTL and
provided strong evidence for selection.Th cells are also represented. The escape mechanisms described
Escape from CTL has also been observed late in HIVin this review are indicated in boxes and summarized as follows.
infection. Two patients, who for several years had madeVirus may be sequestered in sites that CTLs do not access effec-
tively, such as in the glial cells of the central nervous system. Latent monospecific HLA B27 restricted CTL responses to a
proviruses are rare and occur when proviruses integrate but viral single epitope in Gag, were found to select virus with
genes are not expressed and thus cannot be detected by the im- the same mutation, as they progressed to AIDS (Goulder
mune system. CXCR4-using viruses are unaffected by b-chemo-
et al., 1997a). The mutation changedan arginine to lysinekines released by CTL. Both down-regulation of HLA class I expres-
at position 2 in the peptide. The arginine side chain ission and epitope mutation impair CTL recognition of infected cells.
crucial for binding of peptide to HLA B27 and the lysine-Fas-positive CTL can be killed or inhibited by FasL expression on
infected cells. Responding CTL may exhaust. Deletion of specific containing epitope could not be presented to CTL. In
Th cells compromises the CTL response. both patients, the change was associated with an in-
crease in virus load and progression to AIDS. The rea-
sons for the lateness of escape are not known. PossiblyCD41 T cells. However, the recipient was also given a
very large dose of IL-2, and this may have countered the lysine-virus is partiallydefective; thechange isother-
wise unknown in B clade viruses though it does occurany inhibitory effect of the CTL clone, by activating CD41
T cells and promoting viral replication. An unexpected in about 10% of one of the African strains (clade A). It
is also possible that a change in virus coreceptor usefinding was the appearance of virus in which the region
of the Nef epitope was deleted. The mutantvirus became from CCR5 to CXCR4, which frequently happens late in
infection, facilitates escape because inhibition by thearound 30% of the provirus, impressive for a virus that
must have been attenuated. b-chemokines, released by the CTL, can no longer oc-
cur. If so, this escape would result from changes in twoTwo CTL escape mutants have been described during
acute HIV infection. One patient had an acute virus syn- virus proteins, Gag for the epitope mutation and Env for
the coreceptor change.drome, and prior todeveloping anHIV-specific antibody,
he made a monospecific CTL response to an Env epi- In addition to these documented escapes by HIV, es-
cape from CTL by simian immunodeficiency virus (SIV)tope presented by HLA B44. Over a few weeks viruses
appeared with single mutations in the second residue has also been described. Two macaques immunized
with a Nef peptide epitope, and then infected with SIV,of the epitope, a side chain crucial for binding to the B
pocket of HLA B44. Within a few weeks, 100% of the selected a minor mutant virus in the inoculum that was
poorly recognized by the induced CTL response. Thevirus contained this mutation (i.e., it had reached fixa-
tion). As this happened the CTL response diversified. mutant epitope bound poorly to the presenting MHC
molecule (Mortara et al., 1998). The fact that the immuni-Another acutely infected patient made a monospecific
CTL response to an epitope in Nef presented by HLA zation-induced CTL failed to protect these animals from
infection with SIV stresses the importance of inducingB8 (Price et al., 1997). Over a few weeks, the original
virus was completely replaced by mutants that had ei- broad CTL responses in the current intensive search for
a vaccine.ther altered the epitope at the fifth residue, which is
Minireview
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Because there is clear documentation that a mutant of CTL to recognize cells infected with the wild-type
virus (Klenerman et al., 1995). An interesting conse-virus was selected in each case, these examples offer
convincing evidence that CTL can select escape mu- quence of antagonism would be that neither the mutant
nor the original virus would have the advantage. Theretants. The five HIV-infected persons have important
shared features. In each, there was a dominant CTL would however be selective pressure for the presence
of both sequences, i.e., for a balanced variation at theresponse to a single epitope, and the mutation, which
was selected to fixation, disrupted the ability of the epitope.
Nonmutational Escape of HIV-1 from CTLpeptide to bind to the presenting HLA molecule. The
restricted CTL response to a single epitope is remark- Sequestration. Sequestration of HIV in sites where ac-
cess by CTL is limited, for instance infected glial cellsable, butquite common in the immune response tomany
virus infections. It is often seen, and is sometimes ex- in the brain, must hinder T cell control of the infection
and may make elimination impossible. Similarly, HIV la-treme, in the primary CTL response (reviewed in McMi-
chael and O'Callaghan, 1998) possibly setting the pat- tency, where provirus integrates but does not express, is
an obvious mechanism for avoiding immune responsestern of immunodominance thereafter. Escape must be
relatively easy from a monospecific CTL response, but (see minireview by Siliciano, 1998 [this issue of Cell]).
Some cells exist in this state and this may mean that iteven a loss of, say, one in five epitopes, could still give
mutantvirus a significant advantage. There is one further will be all but impossible to eliminate HIV completely,
either by immune responses or by theuse of drugs. Suchrequirement for escape from CTL, which HIV satisfies:
infected cells must process virus derived from a single cells are rare because the cell activation, necessary for
viral cDNA integration, results in viral gene expression.genome so that all proteins made express the same
mutations. HLA Down-Regulation. Down-regulation of HLA ex-
pression on infected cells is a well-established meansLess direct data imply that selection of escape vari-
ants by CTL is common. The breadth of the CTL re- of escape from CTL by persisting viruses. Herpes vi-
ruses, for example, devote several genes to interferingsponse often seen in HIV-infected persons could result
from a series of escapes from immunodominant epi- with antigen presentation to CTL (reviewed in Wiertz et
al., 1997). Reduced HLA class I expression has beentopes, each followed by a new CTL response and then
further escape. Cross-sectional studies may reveal clues observed in HIV-infected cell lines and recently in HIV-
infected blood T cells; Nef has been clearly implicatedthat this has happened. A number of studies have shown
that when CTLs appear not to recognize the expected in this process (Collins et al., 1998), causing HLA class
I molecules to accumulate in clathrin-coated vesicles inimmunodominant epitopes, the prevalent virus is often
mutated at that epitope (reviewed in Goulder et al., the Golgi area (Le Gall et al., 1998). Using virus marked
with placental alkaline phosphatase, Collins et al. (1998)1997b). However, there is an opposing view, that CTL
escape by epitope mutation is greatly limited by the showed that infected peripheral blood mononuclear
cells (PBMCs) with down-regulated HLA expressionbreadth of the CTL response, and therefore, that escape
does not play a large part in failure to control HIV infec- were relatively resistant to CTL attack. Cells infected
with a Nef-deleted mutant virus did not alter HLA expres-tion (see Goulder et al., 1997b, for discussion and refer-
ences). If a major part of HIV control by CD81 T cells is sion and were fully susceptible to CTL. Although this
avoidance mechanism must be incomplete becauserelease of b-chemokines that inhibit HIV infection of
susceptible cells, rather than direct lysis of infected very strong CTL responses are found in nearly all pa-
tients, any impairment in the efficiency with which CTLscells, there should be less pressure to escape as the
chemokines should inhibit virus regardless of epitope recognize infected cells will have a substantial effect on
virus production. It is noteworthy that the effect of Nefsequences. However, chemokines are released in re-
sponse to specific activation, so activity is likely to be is restricted to HLA-A and -B locus molecules, HLA-C
molecules are not down-regulated. This means that in-greatest in the vicinity of the stimulating cell (infected
with the wild-type virus). fected cells should be resistant to lysis by natural killer
cells, which are normally inhibited by the presence ofThe most striking CTL escapes are seen when epitope
binding to HLA molecules is abrogated. More frequently, HLA-C on potential target cells (Le Gall et al., 1998).
Exhaustion of CTL. Another mechanism of HIV escapesequence changes may not affect binding of peptide to
the HLA molecule, but they could impair T cell recogni- is exhaustion of the responding CTL population. In
lymphocytic choriomeningitis virus (LCMV) infection intion, with several possible outcomes. The T cell may
fully cross-react with the mutant, so no change occurs. mice, high dose infection with a rapidly growing virus
strain results in a lethal infection with an aborted CTLThe variant might not be recognized by the available
CTL clones; different T cell clones may then be selected. response (Moskophidis et al., 1993). Some HIV-infected
patients with strong monoclonal CTL responses in theAlthough the latter has been observed, there are other
examples where it does not happen. Thus, the available acute infection do badly: they may either rapidly select
escape mutants (Borrow et al., 1997) or exhaust (Panta-CTL may not see the mutant, which is known to be
immunogenic in other individuals (Klenerman et al., leo et al., 1994). In chronic infection, however, exhaus-
tion has not been unequivocally shown; responding CTL1995). Impaired Th function, compromising new primary
CTL responses, is one explanation for this. Finally, the tend to persist for years (Kalams et al., 1994).
FasL Expression. Finally, it is well known that activatedvariant may antagonize the existing CTL response: cer-
tain altered epitope peptides do not fully activate CTL T lymphocytes express Fas and may thereby be suscep-
tible to apoptosis on contact with Fas-ligand. Spontane-but instead inhibit their function. Thus, HIV-infected cells
that display the mutant sequence may inhibit the ability ous apoptosis of uninfected CD41 and CD81 T cells
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Adelsberger, J.W., Borrow, P., Saag, M.S., Shaw, G.M., Sekaly, R.P.,frequently occurs in HIV-infected patients. The mecha-
and Fauci, A.S. (1994). Nature 370, 463±467.nisms involved are not fully understood. SIV, and by
Phillips, A.N. (1996). Science 271, 497±499implication HIV, induces Nef-dependent expression of
Pope, M., Betjes, M.G., Romani, N., Hirmand, H., Cameron, P.U.,Fas-ligand on infected T cells, and this may cause apo-
Hoffman, L., Gezelter, S., Schuler, G., and Steinman, R.M. (1994).ptosis of the HIV-specific CTL (Xu et al., 1997). The
Cell 78, 389±398.
immunodeficiency viruses may therefore respond to
Price, D.A., Goulder, P.J.R., Klenerman, P., Sewell, A.K., Easter-CTL attack by fighting back.
brook, P.J., Troop, M., Bangham, C.R.M., and Phillips, R.E. (1997).
Progression to AIDS Proc. Natl. Acad. Sci. USA 94, 1890±1895.
Alongside these processes of escape from the CTL re- Rosenberg, E.S., Billingsley, J.M., Caliendo, A.M.,Boswell, S.L., Sax,
sponse is the relentless decline of CD41 T cells, with P.E., Kalams, S.A., and Walker, B.D. (1997). Science 278, 1447±1450.
an early and permanent loss of those specific for HIV Rowland-Jones, S.L., Tan, R., and McMichael, A.J. (1997). Adv. Im-
(Rosenberg et al., 1997). Priming and maintenance of munol. 65, 277±346.
memory CTL responses are Th dependent, but less so Wiertz, E.J., Mukherjee, S., and Ploegh, H.L. (1997). Mol. Med. Today
3, 116±123.than humoral immunity. In long-term HIV-infected pa-
tients, it is striking that very strong CTL responses are Xu, X., Screaton, G.R., Gotch, F.M., Dong, T., Tan, R., Almond, N.,
Walker, B., Stebbings, R., Kent, K., Nagata, S., et al. (1997). J. Exp.maintained despite the loss of specific Th cells. How-
Med. 186, 7±16.ever, it could well be difficult to initiate new primary CTL
Yang, O.O., Kalams, S.A., Trocha, A., Cao, H., Luster, A., Johnson,responses in infected persons because T cell help is
R.P., and Walker, B.D. (1997). J. Virol. 71, 3120±3128.lacking. Thus new CTL responses, demanded by virus
escape mutations and the steadily increasing virus load,
may not be made. This could lead to a further rise in virus
load and ultimately to collapse of the immune response.
It is probable that all of the processes discussed
above occur. Correction of any one may have marginal
effects, but a coordinated attack on more than one,
coupled with effective control of virus replication by
potent drug combinations, offers hope of effective thera-
peutic assistance to the CTL in controlling HIV infection.
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